Clinical significance of CD13 and epithelial mesenchymal transition (EMT) markers in hepatocellular carcinoma - PubMed (original) (raw)
. 2018 Jan 1;48(1):52-60.
doi: 10.1093/jjco/hyx157.
Hiroshi Wada 1, Hidetoshi Eguchi 1, Hisanori Hatano 1, Kunihito Gotoh 1, Takehiro Noda 1, Daisaku Yamada 1, Tadafumi Asaoka 1, Koichi Kawamoto 1, Hiroaki Nagano 1, Yuichiro Doki 1, Masaki Mori 1
Affiliations
- PMID: 29145632
- DOI: 10.1093/jjco/hyx157
Clinical significance of CD13 and epithelial mesenchymal transition (EMT) markers in hepatocellular carcinoma
Chihiro Yamanaka et al. Jpn J Clin Oncol. 2018.
Abstract
Background & aims: To improve prognosis in patients with hepatocellular carcinoma (HCC), the molecular mechanisms of tumor thrombus formation and metastasis must be clarified. The epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) play crucial roles in tumor invasion and metastasis. This study aimed to reveal the clinical significance of the expression of the functional CSC marker, CD13, and investigate the correlation between CD13 expression and two EMT markers, E-cadherin and vimentin.
Methods: We acquired clinical samples from 86 patients with HCC that underwent radical liver resections. We performed immunohistochemistry to evaluate CD13, E-cadherin and vimentin expression. We investigated the relationships among protein expression levels, clinicopathological factors and prognosis.
Results: Based on CD13 expression, patients were categorized into CD13high (n = 30, 34.9%) and CD13low (n = 56, 65.1%) groups. The mean tumor size was significantly larger in the CD13high group than in the CD13low group (P = 0.049). Compared with the CD13low group, the CD13high group showed significantly earlier recurrences and shorter survival times. In the multivariate analysis, CD13high was an independent prognostic factor for overall survival (hazard ratio, 1.98; P = 0.044). The disease-free survival time was shorter in the vimentin-positive group than that in the vimentin-negative group (P = 0.014). In an analysis of the relationship between CD13 and EMT, there was no significant correlation between CD13 and EMT markers.
Conclusions: Our findings suggested that CD13 enrichment was correlated with early recurrences, and poor prognosis in patients with HCC and that vimentin was associated with early recurrences. CD13 represents a potential therapeutic target for HCC, because CSC regulation and EMT suppression are essential in cancer therapy.
Keywords: CD13; cancer stem cells; epithelial mesenchymal transition; hepatocellular carcinoma; immunohistochemistry.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
- BPTF Associated with EMT Indicates Negative Prognosis in Patients with Hepatocellular Carcinoma.
Xiao S, Liu L, Fang M, Zhou X, Peng X, Long J, Lu X. Xiao S, et al. Dig Dis Sci. 2015 Apr;60(4):910-8. doi: 10.1007/s10620-014-3411-0. Epub 2014 Nov 2. Dig Dis Sci. 2015. PMID: 25362514 - Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC.
Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Zhai X, et al. Med Oncol. 2014 Jun;31(6):970. doi: 10.1007/s12032-014-0970-z. Epub 2014 Apr 30. Med Oncol. 2014. PMID: 24781336 - Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma.
Zhou YM, Cao L, Li B, Zhang RX, Sui CJ, Yin ZF, Yang JM. Zhou YM, et al. Ann Surg Oncol. 2012 May;19(5):1700-6. doi: 10.1245/s10434-011-1772-6. Epub 2011 May 17. Ann Surg Oncol. 2012. PMID: 21584833 - The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer.
Grisetti L, Garcia CJC, Saponaro AA, Tiribelli C, Pascut D. Grisetti L, et al. Cell Prolif. 2024 Aug;57(8):e13641. doi: 10.1111/cpr.13641. Epub 2024 Apr 8. Cell Prolif. 2024. PMID: 38590119 Free PMC article. Review. - The prognostic and therapeutic potential of vimentin in colorectal cancer.
Kalaei Z, Shekarchi AA, Hojjat-Farsangi M, Jalali P, Jadidi-Niaragh F. Kalaei Z, et al. Mol Biol Rep. 2024 Sep 30;51(1):1027. doi: 10.1007/s11033-024-09965-w. Mol Biol Rep. 2024. PMID: 39347868 Review.
Cited by
- CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
Domínguez JM, Pérez-Chacón G, Guillén MJ, Muñoz-Alonso MJ, Somovilla-Crespo B, Cibrián D, Acosta-Iborra B, Adrados M, Muñoz-Calleja C, Cuevas C, Sánchez-Madrid F, Avilés P, Zapata JM. Domínguez JM, et al. J Hematol Oncol. 2020 Apr 7;13(1):32. doi: 10.1186/s13045-020-00865-7. J Hematol Oncol. 2020. PMID: 32264921 Free PMC article. - Long Non-Coding RNAs as Novel Targets for Phytochemicals to Cease Cancer Metastasis.
Rajabi S, Rajani HF, Mohammadkhani N, Ramírez-Coronel AA, Maleki M, Maresca M, Hajimehdipoor H. Rajabi S, et al. Molecules. 2023 Jan 18;28(3):987. doi: 10.3390/molecules28030987. Molecules. 2023. PMID: 36770654 Free PMC article. Review. - CD44v6+ Hepatocellular Carcinoma Cells Maintain Stemness Properties through Met/cJun/Nanog Signaling.
Chen W, Wang R, Zhao Y, Li Y, Wang X, Peng W, Bai S, Zheng M, Liu M, Cheng B. Chen W, et al. Stem Cells Int. 2022 Nov 7;2022:5853707. doi: 10.1155/2022/5853707. eCollection 2022. Stem Cells Int. 2022. PMID: 36387747 Free PMC article. - Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies.
Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, Yang S, Gong Z, Lai PBS, Chen GG. Wang N, et al. Ther Adv Med Oncol. 2018 Dec 21;10:1758835918816287. doi: 10.1177/1758835918816287. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30622654 Free PMC article. Review. - Role of microRNA-regulated cancer stem cells in recurrent hepatocellular carcinoma.
Li L, Xun C, Yu CH. Li L, et al. World J Hepatol. 2022 Dec 27;14(12):1985-1996. doi: 10.4254/wjh.v14.i12.1985. World J Hepatol. 2022. PMID: 36618329 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous